IN

Earnings

Here's a Profit Play for a Shaky Earnings Season Kickoff

by

This week, it's all about "TBTF" banks – as in, "too big to fizzle."

There's a lot riding on the financials, but I'm looking at pharma and healthcare, too, and I'll tell you why in a minute.

Fact is, this is one of the most important earnings seasons in recent memory, and investors are flat-out worried that it'll be one of the worst earnings seasons in recent memory.

JPMorgan Chase & Co. officially kicked off Q1 earnings season on Friday with a welcome revenue beat that nudged stocks gently upward for the day.

On the other hand, Bank of America Corp. reported a bumper crop of profits on Monday, but the shares slumped anyway because CFO Paul Donofrio voiced concerns about the slowing pace of interest rates – a big driver of bank profits.

Same deal with Goldman Sachs: It had a convincing earnings beat and a tasty dividend hike, but a drop in trading revenue sent the shares lower.

That shares didn't necessarily take off is a pretty good indicator of the worry out there in the streets. Freaked-out investors are punishing stocks for "sins" they might've forgiven two or three quarters back.

Me? I'm not sure it'll be the worst earnings season in years, but it's certainly going to be the one of most eventful.

Because, remember, it doesn't matter if a stock goes up or down on good or bad earnings. It just has to move...

Trading Strategies

When Science Meets Marijuana, Massive Profits Follow

by

Just last week, I spent two days at the 2019 Cannabis Science Conference East here in my hometown of Baltimore, Md.

The operative word there is "science," and let me tell you, there is a lot of science driving the cannabis market forward that will lead to a ton of profit opportunities.

We're mapping genomes, studying plant fertilization, and learning how to prescribe cannabis to treat ailments as quickly and effectively as possible.

Over the course of two days, there were over 60 presentations covering topics ranging from equipment and methods to analyze cannabis plants, extracts, and cannabinoids; techniques to optimize cultivation; and the latest developments in medical cannabis research.

The companies most adept at deploying the latest science has to offer will enjoy much higher profit margins than those slow to adapt.

But the science goes far beyond the field or greenhouse.

And where it starts and just how far it goes says a lot about how to best play the booming cannabis industry and get closer to life-changing wealth...